Advertisement

Principles of Total Intravenous Anesthesia

Chapter

Abstract

Anesthesiology, like any other specialty in medicine, is continuously evolving. Perhaps the most important changes are driven by applications of physics leading to improved monitoring, as well as by advances in pharmacology (e.g., improved understanding of drug targets). TIVA (total intravenous anesthesia) is an extension of the concept of balanced anesthesia using real-time pharmacokinetic modeling, delivering all anesthetic drugs via intravenous route targeted to achieve optimal operating conditions with maximal patient comfort and safety. However, there is a natural reluctance among physicians, in general, and anesthesiologists, in particular, to change their practice unless the advantages are striking or the established techniques are proven unsafe. This is probably the main reason why intravenous anesthesia is not being embraced as fondly as one might have expected. Coupled with this, the issues related to modalities of administration are not yet perfected and the pharmacological principles on which they are based are constantly evolving. The aim of the chapter is to explore briefly the intricacies of intravenous anesthesia, examine the potential advantages, briefly review the disadvantages, and wrap up with the areas where it is inevitable and areas where it is immensely useful.

Keywords

Pharmacokinetic Model Effect Site Intravenous Anesthesia Inhalational Anesthesia Inhalational Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

References

  1. 1.
    Nagelhout JJ, Plaus K. Nurse anesthesia. Philadelphia: Elsevier Health Sciences; 2009.Google Scholar
  2. 2.
    Guit JB, Koning HM, Coster ML, Niemeijer RP, Mackie DP. Ketamine as analgesic for total intravenous anaesthesia with propofol. Anaesthesia. 1991;46(1):24–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Minto CF, Schnider TW. Contributions of PK/PD modeling to intravenous anesthesia. Clin Pharmacol Ther. 2008;84(1):27–38.PubMedCrossRefGoogle Scholar
  4. 4.
    Shafer SL, Stanski DR. Defining depth of anesthesia. Handb Exp Pharmacol. 2008;182:409–23.PubMedCrossRefGoogle Scholar
  5. 5.
    Absalom AR, Mani V, De Smet T, Struys MMRF. Pharmacokinetic models for propofol–defining and illuminating the devil in the detail. Br J Anaesth. 2009;103(1):26–37.PubMedCrossRefGoogle Scholar
  6. 6.
    Bressan N, Moreira AP, Amorim P, Nunes CS. Target controlled infusion algorithms for anesthesia: theory vs practical implementation. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:6234–7.PubMedGoogle Scholar
  7. 7.
    Hijazi Y, Bodonian C, Bolon M, Salord F, Boulieu R. Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. Br J Anaesth. 2003;90(2):155–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Iirola T, Ihmsen H, Laitio R, Kentala E, Aantaa R, Kurvinen J-P, et al. Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients. Br J Anaesth. 2012;108(3):460–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Levitt DG, Schnider TW. Human physiologically based pharmacokinetic model for propofol. BMC Anesthesiol. 2005;5(1):4.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Masui K, Upton RN, Doufas AG, Coetzee JF, Kazama T, Mortier EP, et al. The performance of compartmental and physiologically based recirculatory pharmacokinetic models for propofol: a comparison using bolus, continuous, and target-controlled infusion data. Anesth Analg. 2010;111(2):368–79.PubMedCrossRefGoogle Scholar
  11. 11.
    Bienert A, Wiczling P, Grześkowiak E, Cywiński JBJ, Kusza K. Potential pitfalls of propofol target controlled infusion delivery related to its pharmacokinetics and pharmacodynamics. Pharmacol Rep. 2012;64(4):782–95.PubMedCrossRefGoogle Scholar
  12. 12.
    Sear JW, Glen JB. Propofol administered by a manual infusion regimen. Br J Anaesth. 1995;74(4):362–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Kim HS, Park HJ, Kim CS, Lee JR. Combination of propofol and remifentanil target-controlled infusion for laryngeal mask airway insertion in children. Minerva Anestesiol. 2011;77(7):687–92.PubMedGoogle Scholar
  14. 14.
    Russell D, Wilkes MP, Hunter SC, Glen JB, Hutton P, Kenny GN. Manual compared with target-controlled infusion of propofol. Br J Anaesth. 1995;75(5):562–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Ithnin F, Lim Y, Shah M, Shen L, Sia ATH. Tracheal intubating conditions using propofol and remifentanil target-controlled infusion: a comparison of remifentanil EC50 for Glidescope and Macintosh. Eur J Anaesthesiol. 2009;26(3):223–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Maruyama K, Nishikawa Y, Nakagawa H, Ariyama J, Kitamura A, Hayashida M. Can intravenous atropine prevent bradycardia and hypotension during induction of total intravenous anesthesia with propofol and remifentanil? J Anesth. 2010;24(2):293–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Ouattara A, Boccara G, Lemaire S, Köckler U, Landi M, Vaissier E, et al. Target-controlled infusion of propofol and remifentanil in cardiac anaesthesia: influence of age on predicted effect-site concentrations. Br J Anaesth. 2003;90(5):617–22.PubMedCrossRefGoogle Scholar
  18. 18.
    Nordström O, Engström AM, Persson S, Sandin R. Incidence of awareness in total i.v. anaesthesia based on propofol, alfentanil and neuromuscular blockade. Acta Anaesthesiol Scand. 1997;41(8):978–84.PubMedCrossRefGoogle Scholar
  19. 19.
    Bailey JM. Context-sensitive half-times: what are they and how valuable are they in anaesthesiology? Clin Pharmacokinet. 2002;41(11):793–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology. 1992;76(3):334–41.PubMedCrossRefGoogle Scholar
  21. 21.
    Bürkle H, Dunbar S, Van Aken H. Remifentanil: a novel, short-acting, mu-opioid. Anesth Analg. 1996;83(3):646–51.PubMedGoogle Scholar
  22. 22.
    Coskun D, Celebi H, Karaca G, Karabiyik L. Remifentanil versus fentanyl compared in a target-controlled infusion of propofol anesthesia: quality of anesthesia and recovery profile. J Anesth. 2010;24(3):373–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Mingo OH, Ashpole KJ, Irving CJ, Rucklidge MWM. Remifentanil sedation for awake fibreoptic intubation with limited application of local anaesthetic in patients for elective head and neck surgery. Anaesthesia. 2008;63(10):1065–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Komatsu R, Turan AM, Orhan-Sungur M, McGuire J, Radke OC, Apfel CC. Remifentanil for general anaesthesia: a systematic review. Anaesthesia. 2007;62(12):1266–80.PubMedCrossRefGoogle Scholar
  25. 25.
    Suttner S, Boldt J, Schmidt C, Piper S, Kumle B. Cost analysis of target-controlled infusion-based anesthesia compared with standard anesthesia regimens. Anesth Analg. 1999;88(1):77–82.PubMedGoogle Scholar
  26. 26.
    Alhashemi JA, Miller DR, O’Brien HV, Hull KA. Cost-effectiveness of inhalational, balanced and total intravenous anaesthesia for ambulatory knee surgery. Can J Anaesth. 1997;44(2):118–25.PubMedCrossRefGoogle Scholar
  27. 27.
    Sung YF, Reiss N, Tillette T. The differential cost of anesthesia and recovery with propofol-nitrous oxide anesthesia versus thiopental sodium-isoflurane-nitrous oxide anesthesia. J Clin Anesth. 1991;3(5):391–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Sneyd JR, Holmes KA. Inhalational or total intravenous anaesthesia: is total intravenous anaesthesia useful and are there economic benefits? Curr Opin Anaesthesiol. 2011;24(2):182–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Dong Y, Zhang G, Zhang B, Moir RD, Xia W, Marcantonio ER, et al. The common inhalational anesthetic sevoflurane induces apoptosis and increases beta-amyloid protein levels. Arch Neurol. 2009;66(5):620–31.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Tang J, Eckenhoff MF, Eckenhoff RG. Anesthesia and the old brain. Anesth Analg. 2010;110(2):421–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Wei H, Liang G, Yang H, Wang Q, Hawkins B, Madesh M, et al. The common inhalational anesthetic isoflurane induces apoptosis via activation of inositol 1,4,5-trisphosphate receptors. Anesthesiology. 2008;108(2):251–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Wrońska-Nofer T, Palus J, Krajewski W, Jajte J, Kucharska M, Stetkiewicz J, et al. DNA damage induced by nitrous oxide: study in medical personnel of operating rooms. Mutat Res. 2009;666(1–2):39–43.PubMedCrossRefGoogle Scholar
  33. 33.
    Boivin JF. Risk of spontaneous abortion in women occupationally exposed to anaesthetic gases: a meta-analysis. Occup Environ Med. 1997;54(8):541–8.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Goudra BG, Mandel JE. Target-controlled infusions/patient-controlled sedation. Tech Gastrointest Endosc. 2009;11(4):181–7.CrossRefGoogle Scholar
  35. 35.
    Sulbaek Andersen MP, Nielsen OJ, Wallington TJ, Karpichev B, Sander SP. Medical intelligence article: assessing the impact on global climate from general anesthetic gases. Anesth Analg. 2012;114(5):1081–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Basavana Gouda Goudra
    • 1
    • 2
  • Preet Mohinder Singh
    • 3
  1. 1.Department of Anesthesiology and Critical Care MedicineHospital of the University of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of Clinical Anesthesiology and Critical CarePerelman School of MedicinePhiladelphiaUSA
  3. 3.Department of AnesthesiaAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations